• LAST PRICE
    53.7000
  • TODAY'S CHANGE (%)
    Trending Down-1.0200 (-1.8640%)
  • Bid / Lots
    51.6000/ 5
  • Ask / Lots
    54.7200/ 5
  • Open / Previous Close
    54.3500 / 54.7200
  • Day Range
    Low 52.8450
    High 55.0500
  • 52 Week Range
    Low 29.2337
    High 62.5300
  • Volume
    769,960
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 15, 2024

      Show headlines and story abstract
    • 9:00AM ET on Friday Nov 15, 2024 by Dow Jones
      Companies Mentioned: CRNX

      Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

      SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY, and both the Citi Global Healthcare Conference and the Evercore 7th Annual HealthCONx Conference are taking place in Miami, FL.
  • Nov 14, 2024

      Show headlines and story abstract
    • 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: CRNX

      difficult or costly to protect such rights; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity, unexpected adverse side effects or inadequate efficacy of the company's product candidates that may limit their development, regulatory approval and/or commercialization; the company's dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics' clinical and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; Crinetics may use its capital resources sooner than expected; any future impacts to our business resulting from geopolitical developments outside our control; and the other risks and uncertainties described in the company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and its Quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
    • 1:44PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: CRNX

      Ratings actions from Benzinga: https://www.benzinga.com/quote/CRNX/analyst-ratings

      (END) Dow Jones Newswires

      November 14, 2024 13:44 ET (18:44 GMT)
  • Nov 13, 2024

  • Nov 12, 2024

Peers Headlines